Skip to content

Comparison of RF and crYoballoon ablatiOn Therapy of AF(CRYO-AF)

Cryoballoon Versus Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: A Multi-center, Prospective, Randomized, Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03044951
Acronym
CRYO-AF
Enrollment
600
Registered
2017-02-07
Start date
2016-11-30
Completion date
2020-12-31
Last updated
2017-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, cryoablation, irrigated radiofrequency ablation, pulmonary vein isolation

Brief summary

It's a multi-center, prospective, randomized, controlled clinical trial of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation.

Detailed description

The hypothesis of this study is that pulmonary vein isolation with cryoballoon ablation is not inferior to radiofrequency ablation with 3D mapping with respect to clinical safety and efficacy.

Interventions

PROCEDUREcryoballoon ablation

cryoballoon ablation:pulmonary vein isolation by cryoballoon

PROCEDUREradiofrequency ablation

radiofrequency ablation: pulmonary vein isolation by radiofrequency energy

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* ECG recording of atrial fibrillation * first time of ablation * refractory to at least one anti-arrhythmia drug * sign informed consent for participation in the study

Exclusion criteria

* had ablation before * serious heart failure * left atrial diameter\>55mm * Myocardial infarction, heart surgery or coronary intervention in 3 months before the ablation * Stroke in 6 months before the ablation * Endocardial thrombosis

Design outcomes

Primary

MeasureTime frameDescription
Efficacy endpoint (time to first documented clinical recurrence after blanking period)one yearthe time to first documented clinical recurrence after blanking period (month)
Safety endpoint (Any procedure-related complications)one yearAny procedure-related complications

Secondary

MeasureTime frameDescription
X-ray time (min)one year
Procedure time (min)one yearskin to skin
QoL changes at 12 months (Units on a Scale)one year
time to first time cardiovascular hospitalization (month)one year
Left atrial time (min)one year

Countries

China

Contacts

Primary ContactQi Jin
jinqi127@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026